C17ORF53
Reactivity: Human, Mouse, Rat
WB, IF (p)
Host: Rabbit
Polyclonal
AbBy Fluor® 680
Application Notes
ELISA: 1:10000, WB: 1:500 - 1:2000
Restrictions
For Research Use only
Format
Liquid
Buffer
Ascitic fluid containing 0.03 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C/-20 °C
Storage Comment
4°C, -20°C for long term storage
Styrkarsdottir, Halldorsson, Gretarsdottir, Gudbjartsson, Walters, Ingvarsson, Jonsdottir, Saemundsdottir, Snorradóttir, Center, Nguyen, Alexandersen, Gulcher, Eisman, Christiansen, Sigurdsson, Kong et al.: "New sequence variants associated with bone mineral density. ..." in: Nature genetics, Vol. 41, Issue 1, pp. 15-7, (2008) (PubMed).
Target
C17orf53 (C17ORF53)
(Chromosome 17 Open Reading Frame 53 (C17ORF53))
chromosome 17 open reading frame 53 antibody, C17orf53 antibody
Background
C17orf53 (chromosome 17 open reading frame 53) is a 647 amino acid protein that is encoded by a gene mapping to human chromosome 17. Chromosome 17 makes up over 2.5 % of the human genome with about 81 million bases encoding over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes. Chromosome 17 is also linked to neurofibromatosis, a condition characterized by neural and epidermal lesions, and dysregulated Schwann cell growth. Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease are also associated with chromosome 17. , ,